Cancer patients in the UK are being given a new immunotherapy treatment at Imperial College Healthcare NHS Trust as part of a global phase 1/2 clinical
trial, which aims to evaluate its safety and potential for treating 'solid tumour' cancers such as melanoma and lung cancer.
The experimental therapy, called mRNA-4359, has been designed to train patients' immune systems to recognise and fight cancer cells, according to researchers
at Imperial College London.
For the first time in the UK, cancer patients received the treatment at the National Institute for Health and Care Research (NIHR) Imperial Clinical Research
Facility at Hammersmith Hospital.
In this non-randomised trial, mRNA-4359 is administered to patients either alone or in combination with an existing cancer drug called pembrolizumab, a type of
immune checkpoint inhibitor.
The researchers are hopeful that this new therapeutic approach, if proven to be safe and effective in clinical trials, could lead to a new treatment option for
difficult-to-treat cancers.
Dr Nik Kotecha OBE, chairman of Morningside Pharmaceuticals and the Randal Charitable Foundation, has won the Distinguished Alumni Award at Imperial College
London's Alumni Awards 2022.
The annual awards honour outstanding alumni who have demonstrated sustained excellence in their personal and professional achievements and have made a substantial impact on society.
Dr Kotecha, who founded Morningside in 1991, which manufactures and supplies generic and branded medicines to the UK and globally, said: "I'm thrilled to be honoured by the university in this way.
"As a child growing up in Leicester my family had very little, but I was fortunate to be given opportunities to gain a good education. After finishing my degree in Newcastle; Professor Steve Ley FRS at Imperial College took a chance in accepting me into his eminent group and this really was the opportunity I needed to forge a career.
Canadian imperial vapers and canadian e-juice presents Coffee dark roast. Top and rich flavour best for sugar patient because coffee dark roast is sugar free.
Canadian Imperial Vapers, E Cigarette, Canadian flavor crafter with custom E Liquids, Hardware batteries Kangertech EGO Kits DIY nicotine and anything vaping related.
The world's first human challenge trial in which volunteers were deliberately exposed to Covid-19 to advance research into the disease was found to be safe in
healthy young adults, one of the companies running the study said on Wednesday.
The data supports the safety of this model which could theoretically provide a "plug and play" platform for testing therapies and vaccines using the original
Covid-19 strain as well as variants of the virus, Open Orphan, which carried out the study, said in a statement.
Open Orphan is running the project, launched a year ago, with Imperial College London, the UK government's vaccines task force and the clinical company hVIVO.
The trial infected 36 healthy male and female volunteers aged 18-29 years with the original SARS-CoV-2 strain of the virus and closely monitored them in a controlled
quarantined setting. They will be followed up for 12 months after discharge from the quarantine facility.
The new test, which involves the quick removal of growths with the potential to turn cancerous, has been devised following a 16-year-old study, 'The Lancet' reported.
The study of more than 170,000 volunteers aged between 55 and 64 suggested that the examination of the lower colon and rectum reduced deaths by 43 per cent.